HemaCare Co. (OTCMKTS:HEMA – Get Free Report) traded up 0.6% on Thursday . The company traded as high as $25.31 and last traded at $25.31. Approximately 5,400 shares traded hands during mid-day trading, a decline of 86% from the average daily volume of 39,950 shares. The stock had previously closed at $25.16.
HemaCare Price Performance
The company’s 50-day moving average is $25.31 and its 200-day moving average is $25.31.
About HemaCare
HemaCare Corporation is a specialty life sciences company that supplies primary human blood and bone marrow-derived cells for research, drug development and medical device evaluation. The company’s product portfolio includes peripheral blood mononuclear cells (PBMCs), buffy coats, hematopoietic stem and progenitor cells, whole blood, bone marrow aspirates and custom-processed cell fractions. These offerings are designed to support preclinical studies, translational research and in vitro assays across immunology, hematology, oncology and regenerative medicine applications.
In addition to off-the-shelf cell products, HemaCare provides custom cell isolation services, donor screening and logistics solutions tailored to the needs of pharmaceutical, biotechnology and academic customers.
Featured Articles
- Five stocks we like better than HemaCare
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Receive News & Ratings for HemaCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HemaCare and related companies with MarketBeat.com's FREE daily email newsletter.
